Tiny study probes risks of lung cancer combo therapy

NCT ID NCT03705806

Ongoing Knowledge-focused Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed 12 people with stage IV non-small cell lung cancer who received both palliative chest radiation and an immunotherapy drug (nivolumab or pembrolizumab). The goal was to track side effects like radiation-related toxicities and patient quality of life. Researchers hope to learn how to better manage these combined treatments, but the small size means findings are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Radiation therapy (30 Gy in 10 fractions) combined with PD-1 inhibitors (nivolumab or pembrolizumab)
What this could lead to: If successful, this could help doctors better understand and manage side effects when combining radiation and immunotherapy for advanced lung cancer.
What could go wrong: This is a very small observational study (12 people) with no control group, so results may not apply broadly. It only looks at side effects, not whether the combination works better.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER LUNG CANCER, NONSMALL CELL

Contacts and locations

Locations

University Health Network, Princess Margaret Cancer Centre

Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.